Biologic therapy – Chemotherapy – The Royal Marsden Hospital

Survival: 10.5 months
Toxicity Grade: 3
Treatments: Biologic therapy
Drugs: Mitozytrex
Country: United Kingdom
City/State/Province: Sutton
Hospital: The Royal Marsden Hospital
Journal: Link
Date: 2/2002


Patients: This Phase I study involved 13 patients with malignant mesothelioma.

Treatment: The treatment consisted of a suspension of heat-killed Mycobacterium vaccae (SRL172), a fast growing avirulent mycobacterium, that may have non-specific immunomodulating properties in combination with standard chemotherapy (mitomycin-C (mitozytrex), vinblastine (velban) and cisplatin (platinol)).

Toxicity: Grade 1-3 toxicities included infection, emesis, mucositis, diarrhea, constipation, alopecia, neuropathy, fatigue, and hematological.

Results: The median overall survival was 10.5 months.

Support: This study was supported by a research grant from SR Pharma. SR Pharma markets SRL172.

Correspondence: MER O’Brien, MD

Get your free copy of
“Surviving Mesothelioma” Today!